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Pancreatic ductal adenocarcinoma (PDA) is a lethal disease. Overall survival is typically six 
months from diagnosis1. Numerous phase III trials of agents effective in other malignancies 
have failed to benefit unselected PDA populations, although patients do occasionally 
respond. Studies in other solid tumors have shown that heterogeneity in response is 
determined, in part, by molecular differences between tumors. Further, treatment outcomes 
are improved by targeting drugs to tumor subtypes in which they are selectively effective, 
with breast2 and lung3 cancers providing recent examples. Identification of PDA molecular 
subtypes has been frustrated by a paucity of tumor specimens available for study. We have 
overcome this problem by combined analysis of transcriptional profiles of primary PDA 
samples from several studies along with human and mouse PDA cell lines. We define three 
PDA subtypes: classical, quasi-mesenchymal, and exocrine-like, and present evidence for 
clinical outcome and therapeutic response differences between them. We further define gene 
signatures for these subtypes that may have utility in stratifying patients for treatment and 
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present preclinical model systems that may be used to identify new subtype specific 
therapies.
Global gene expression analysis has proved useful for subtype identification in many human 
tumor types4. We approached PDA subtype identification by first identifying intrinsically 
variable (standard deviation > 0.8) genes in two gene expression microarray datasets from 
resected PDA. We generated one dataset using microdissected PDA material (UCSF tumors, 
n=27) from clinical samples for which information on survival duration was available and 
the second was previously published (Badea, et al.)5. To increase power, we merged these 
two datasets using the distance weighted discrimination (DWD) method6,7 and included 
intrinsically variable genes common to both studies. We then performed nonnegative matrix 
factorization (NMF) analysis with consensus clustering8 to identify subtypes of the disease. 
This analysis supported up to three subtypes (cophenetic coefficient >0.99; Supplementary 
Figs. 1, 2a and Supplementary Tables 1–3). We then developed a gene signature by using 
subtypes defined in NMF analysis of the merged clinical datasets to supervise significance 
analysis of microarrays (SAM) analysis9 with false discovery rate (FDR) less than 0.001. 
This resulted in a 62 gene signature, designated PDAssigner. The three PDA subtypes in the 
merged clinical dataset and their expression of PDAssigner genes are shown in Fig. 1a. We 
designated these subtypes as classical, quasi-mesenchymal (QM-PDA) and exocrine-like, 
based on our interpretation of subtype specific gene expression. The classical subtype had 
high expression of adhesion-associated and epithelial genes, the QM-PDA subtype showed 
high expression of mesenchyme associated genes. The exocrine-like subtype showed 
relatively high expression of tumor cell derived digestive enzyme genes, with 
immunohistochemical staining supporting this observation (Supplementary Fig. 3). Analysis 
of PDAssigner gene expression in three additional published PDA expression datasets of 
unique origin, platform or processing10–12 also supported these three subtypes 
(Supplementary Fig. 4) demonstrating the robust nature of the subtype classification in early 
stage PDA.
Survival after PDA resection has been associated with many factors including stage (tumor 
size and nodal involvement) and grade (degree of differentiation)13, but no one factor has 
been consistently prognostic14,15. We found that stratification by PDA transcriptional 
subtype provided useful prognostic information in one PDA dataset (UCSF) for which 
clinical annotation was available. Specifically, patients with classical subtype tumors fared 
better than patients with QM-PDA subtype tumors after resection (p=0.038, log rank, Fig. 
1b). In this same data set, stage and grade were not significantly related (p>0.99), stage was 
not significantly associated with subtype (p=0.40), while grade was (p=0.041) (univariate 
analyses). In a multivariate Cox regression model including stage and subtype, subtype was 
an independent predictor of overall survival (p=0.024) indicating that PDA subtype 
independently contributed prognostic information to pathological staging in PDA. 
Associations of PDA subtype with other clinical variables are summarized in Supplementary 
Table 4. This analysis supports the use of subtypes (as defined using PDAssigner) as an 
independent prognostic indicator in resected PDA.
Further validation of PDA subtypes and preclinical identification of subtype specific 
therapeutic agents would be facilitated by the availability of laboratory models of the 
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subtypes. Therefore, we asked if the PDA subtypes were represented in a collection of 19 
human and 15 mouse PDA cell lines. The 19 human PDA cell lines were selected from 
publicly available PDA lines while the 15 mouse lines were derived by us from genetically 
engineered Tp53−/− and INK4A−/−16 models of PDA. The analyses of the human and mouse 
PDA cell lines using the 62 PDAssigner genes are shown in Fig. 1c,d, as well as in 
Supplementary Figs. 2b–e. Supplementary Tables 5 and 6. These cell line collections 
contain representatives of the classical and QM-PDA subtypes, but not the exocrine-like 
subtype. The absence of the exocrine-like subtype in the cell line collection raises the 
possibility that this subtype is an artifact of contaminating normal pancreas tissue adjacent to 
tumor. However, the UCSF samples were prepared by microdissection to enrich for PDA 
cancer cells thereby minimizing contaminating tumor-associated stroma and/or adjacent 
normal exocrine pancreas. This dataset includes the exocrine-like subtype, which argues that 
it is a bona fide PDA subtype. Thus, we conclude that the cell line collections model two of 
the PDA subtypes thereby enabling exploration of biological differences between these two 
PDA subtypes and may facilitate screening for classical and QM-PDA subtype-specific 
therapeutic agents and biological properties.
Two genes associated with PDA subtypes, GATA binding protein 6 (GATA6) and v-ki-ras2 
kirsten rat sarcoma viral oncogene homolog (KRAS), two variable genes in our UCSF PDA 
dataset, Supplementary Table 1a), have been implicated in both aspects of normal 
development and cancer pathophysiology in published studies. GATA-family transcription 
factors are associated with tissue specific differentiation and have been demonstrated to be 
subtype specific markers in other cancers. For example, GATA binding protein 3 (GATA3) 
is required for luminal differentiation in the breast17, and high GATA3 characterizes luminal 
subtype breast cancers18. Likewise, GATA6 is essential for pancreatic development19 and 
has been implicated in PDA20,21. GATA6 is highly expressed in most classical subtype 
tumors and cell lines, and comparatively low in the QM-PDA cell lines and tumors. 
Additionally, a previously published gene signature associated with GATA6 
overexpression20 is enriched in the classical subtype (Supplementary Fig. 5). Seeking to 
establish a possible functional role underlying the observed differences in GATA6 
expression, we assessed the impact of GATA6-directed RNAi knockdown on colony 
formation in soft agar in the classical and QM-PDA cell lines. GATA6 depletion impaired 
anchorage-independent growth in classical PDA cell lines, but not in QM-PDA cell lines 
(Fig. 2), consistent with a functional, subtype-specific role for this transcription factor in the 
classical PDA subtype.
Recent work in the mouse demonstrates that PDA can arise from a variety of precursor cells 
by activating KRAS in distinct cellular compartments of the pancreas22. Others have found 
that cancer cell lines harboring mutant KRAS differ in their dependence on KRAS23. These 
findings imply plasticity in either reliance on KRAS signaling or a cell-type specific role for 
mutant KRAS in different cells of origin/lineages in PDA, or both. They further suggested to 
us that despite KRAS mutation in most PDAs, KRAS dependence might differ by PDA 
subtype. We found KRAS mRNA levels elevated in classical subtype PDAs relative to the 
other subtypes (Supplementary Fig. 6, p<0.05 in UCSF samples). We explored the 
relationship between KRAS dependence and subtype by using RNAi to probe KRAS-mutant 
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human PDA cell lines for dependence on KRAS. Classical PDA lines proved to be relatively 
more dependent on KRAS than QM-PDA lines (Fig. 3). Further, a previously reported 
signature of KRAS-addiction23 is enriched in the classical subtype (Supplementary Fig. 7). 
These results suggest that KRAS-directed therapy, while not yet a clinical reality, might be 
best deployed in classical PDA. Mouse models capable of sequentially activating and then 
deleting mutant KRAS would further these observations to genetically define the respective 
roles mutant KRAS plays in both the initiation and ongoing maintenance of PDA.
We tested the possibility that PDA subtypes with different biological characteristics might 
have subtype-specific drug responses by measuring responses to gemcitabine and erlotinib 
(the backbone of current treatment regimens24) in human PDA cell lines of known subtype. 
QM-PDA subtype lines were, on average, more sensitive to gemcitabine than the classical 
subtype (Fig. 4). Conversely, erlotinib was more effective in classical subtype cell lines. 
This suggests that KRAS mutation status is an imperfect predictor of sensitivity to EGFR-
targeted therapy in PDA, an observation consistent with findings in nonsmall cell lung25 and 
colorectal cancers26, and implies that cancer cells dependent on mutant KRAS still employ 
the EGFR to some extent. These results further establish phenotypic differences between the 
classical and QM-PDA subtypes, and suggest that these and perhaps additional drugs will 
show subtype specificity in PDA, a distinction that could be exploited in clinical trial 
sensitivity enrichment schemes. More immediately, these results indicate that gemcitabine 
and erlotinib are preferentially active in different PDA subtypes, so that the current practice 
of combining them may increase toxicity without increasing efficacy for many patients. 
Combining agents with similar subtype specificity might be considered instead.
In summary, our data support the existence of three intrinsic subtypes of PDA that progress 
at different rates clinically and may respond differently to selected therapies. The validity of 
these subtypes is supported by analysis of multiple primary clinical datasets as well as of 
PDA cell lines both from human tumors and from mouse models engineered with the 
hallmark genetic lesions of human PDA. Knowledge of these subtypes may motivate 
investigation of associations between clinico-pathologic variables and these subtypes by 
collaborative consortia examining the molecular diversity of PDA27. The markers that 
define these subtypes may have prognostic utility in risk-adapted surgical approaches28 or 
predictive utility in sensitivity enrichment schemes. The use of subtyped human and mouse 
PDA preclinical models promises to accelerate identification of subtype specific functional 
and regulatory processes that can be exploited to therapeutic benefit. In turn, such assay 
systems could be used to screen therapeutic approaches, empirically or based on mechanism, 
to identify those that are potent against PDA, either in a specific subtype that would then be 




After institutional review board approval, we selected archival material from pancreatic 
ductal adenocarcinoma resections performed at the University of California, San Francisco 
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between 1993 and 2006. G.E.K. reviewed all cases prior to inclusion in the study. Tissue 
processing is described in Supplementary Methods.
Merging of Microarray Datasets
After processing of microarrays (as described in Supplementary Information), we screened 
the UCSF and Badea et al.,5 PDA datasets separately by selecting probes with standard 
deviation (SD) > 0.8. We then merged SD-selected datasets using DWD7 as described6. We 
column (samples) normalized to N(0,1) and row (probe or gene) normalized each dataset by 
median centering. We merged the processed datasets using DWD and finally, we median 
centered the rows.
NMF and SAM Analysis
We analyzed the merged datasets by consensus clustering-based NMF8 to identify stable 
subtypes using R code from GenePattern30. See supplement for details regarding the 
interpretation of subtypes derived from consensus-based NMF clustering. We identified 
PDAssigner genes using three-class SAM analysis based on classes identified from NMF 
analysis using the Bioconductor31 package, Siggenes, and generated heatmaps of samples by 
PDAssigner genes using Cluster software32. For cell line classification, we merged the cell 
line datasets with core PDA clinical datasets after selection of the 62 PDAssigner genes 
from each dataset followed by DWD based merging. We visualized datasets using the 
Hierarchical Clustering Viewer (HCV) from GenePattern30.
Clinical Outcome Analysis
We calculated overall survival in days from the time of PDA resection until date of death as 
defined by the State of California Death Registry and clinical records. We employed the log-
rank test for univariate associations with survival or the Cox proportional hazards model for 
multivariate modeling of survival. We applied Fisher’s exact test to investigate the 
relationships among subtype, stage and grade. We used the R language for all analyses. We 
drew the survival curve using web-based GenePattern30.
Drug Sensitivity
We plated 2.5x103 cells per well on day 0, treated with erlotinib or gemcitabine in nine, 
five-fold serial dilutions on day 1 and estimated cell number using Cell Titre Glow assay 
(CTG, Promega) on day 4. IC50 was calculated using the Calcusyn program (Biosoft).
RNAi
We obtained validated pLKO-based shRNA vectors shKRAS#533 from Dr. B.R. Stockwell 
(NYU) and shGATA6#5, and shLuc34 from Dr. R Adam, (Boston Children’s Hospital). We 
packaged lentiviruses, transduced cells and then selected in puromycin for 48 hours. For 
shKRAS proliferation experiments, we plated 2.5 x103 transduced cells per well on day 0 in 
96 well plates, then counted one plate on day one and the other plate on day four. We 
confirmed protein knockdown by western blotting using the Odyssey system, with 10ug per 
lane of total protein and the c19 KRas antibody (Santa Cruz), normalized to total actin (I-19, 
Santa Cruz) and compared to pLKOshLuc -KRas levels. For GATA6 knockdown 
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experiments, after puromycin selection cells we trypsinized and plated transduced cells in 
soft agar as described35. We assessed GATA6 transcript levels on the day of plating in soft 
agar as described34.
See Supplementary Information for detailed methods.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Subtypes of PDA in tumors and cell lines and their prognostic significance
A. Heatmap (HM) showing three subtypes of PDA in a DWD-merged UCSF and Badea et 
al.5 PDA microarray datasets using the PDAssigner geneset. B. Kaplan-Meier Survival 
curve comparing survival of classical (red), QM-PDA (blue) and exocrine-like (green) 
subtype patients. Survival time is in days (d). p-value is by Log-rank test. C. HM showing 
three subtypes of PDA in a DWD-merged core clinical and human PDA cell line microarray 
datasets using the PDAssigner geneset. D. HM showing three subtypes of PDA in a DWD-
merged core clinical PDA and mouse PDA cell line microarray datasets using PDAssigner 
geneset. In the top bar, magenta marks classical subtype PDA, yellow marks QM-PDA and 
light blue marks exocrine-like (by NMF). The second from top bar denotes sample set of 
origin, with brown samples originating from UCSF, orange samples originating from Badea 
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et al.5 PDA datasets and gray samples originating from either human (C) or mouse (D) PDA 
cell lines. The bars on the side denote PDAssigner genes upregulated in classical (violet), 
QM-PDA (gray) and exocrine-like (green).
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Figure 2. Classical PDA subtype and the GATA6 transcription factor
A. Relative log expression of GATA6 in PDA cell lines, transduced with shRNA against 
GATA6 or control, was determined by qRT-PCR. Black columns are classical lines, gray 
columns are QM-PDA lines, note log scale. B. Colonies per Low Powered Field (LPF) in 
PDA cell lines transduced with shRNA against GATA6 or control.
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Figure 3. Classical subtype cells depend on KRas
A. PDA lines (all with GTPase inactivating KRAS mutations), were transduced with 
lentiviruses encoding either control (shLUC) or KRAS (shKRAS) directed RNAi. Relative 
proliferation is plotted. Black columns are classical lines and gray columns are QM-PDA 
lines. B. Box plot of relative proliferation of classical and QM-PDA human PDA cell lines. 
p-values by the Kruskal-Wallis test.
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Figure 4. Drug Responses Differ by Subtype
IC50 in negative log10 of drug concentration is plotted for each cell line tested with A. 
gemcitabine and C. erlotinib. Black columns are classical lines and gray columns are QM-
PDA lines. Box Plot of IC50 of classical and QM-PDA human PDA cell lines for B. 
gemcitabine and D. erlotinib, p-values represent statistics using Kruskal-Wallis test.
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